The option has a per share exercise price equal to the closing sales price of Adverum's common stock on NASDAQ on the grant date, and will vest over four years, subject to her continued service with Adverum. About Adverum Biotechnologies, Inc. Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD).